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ORIGINAL ARTICLE
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Background: Advanced melanoma treatments often rely on immunotherapy or targeting mutations, with few treatment
options for wild-type BRAF (BRAF-wt) melanoma. However, the mitogen-activated protein kinase pathway is activated in most
melanoma, including BRAF-wt. We assessed whether inhibiting this pathway by adding kinase inhibitors trametinib or
pazopanib to paclitaxel chemotherapy improved outcomes in patients with advanced BRAF-wt melanoma in a phase II,
randomised and open-label trial.
Patients and methods: Patients were randomised (1 : 1 : 1) to paclitaxel alone or with trametinib or pazopanib. Paclitaxel
was given for a maximum of six cycles, while 2mg trametinib and 800mg pazopanib were administered orally once daily
until disease progression or unacceptable toxicity. Participants and investigators were unblinded. The primary end
point was progression-free survival (PFS). Key secondary end points included overall survival (OS) and objective response
rate (ORR).
Results: Participants were randomised to paclitaxel alone (n¼ 38), paclitaxel and trametinib (n¼ 36), or paclitaxel and
pazopanib (n¼ 37). Adding trametinib significantly improved 6-month PFS [time ratio (TR), 1.47; 90% confidence interval (CI)
1.08–2.01, P¼ 0.04] and ORR (42% versus 13%; P¼ 0.01) but had no effect on OS (P¼ 0.25). Adding pazopanib did not benefit 6-
month PFS; (TR 1.36; 90% CI 0.96–1.93; P¼ 0.14), ORR, or OS. Toxicity increased in both combination arms.
Conclusion: In this phase II trial, adding trametinib to paclitaxel chemotherapy for BRAF-wt melanoma improved PFS and
substantially increased ORR but did not impact OS.
This study was registered with the EU Clinical Trials Register, EudraCT number 2011-002545-35, and with the ISRCTN registry,
number 43327231.
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Introduction
Although substantial progress has been achieved in themanagement
of unresectable and metastatic melanoma, it remains a fatal disease.
Impressive anticancer activity has been shown by kinase inhibitors,
which target aberrant signalling in the 50% of melanomas with
BRAF mutations, and antibodies that bind to the immune check-
points cytotoxic T-lymphocyte antigen 4 (CTLA-4) or programmed
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death 1 (PD1) [1–3]. However, melanoma patients with wild-type
BRAF (BRAF-wt) have fewer treatment choices, as they do not bene-
fit fromBRAF inhibitor therapy.
Extracellular-signal-regulated kinase (ERK) is constitutively
active in all melanoma, irrespective of its mutation status [4].
ERK is part of the mitogen-activated protein kinase (MAPK)
pathway, which is activated by an upstream kinase called MAPK
kinase, or MEK. Activating ERK through the MAPK pathway
promotes melanoma cell growth and resistance to taxane chemo-
therapy, the latter by inhibiting apoptosis [5]. In pre-clinical
BRAF-wt melanoma models, co-administering a taxane and a
MEK inhibitor substantially induces tumour regression and
apoptosis [6, 7]. A clinical trial of the taxane docetaxel with the
MEK inhibitor selumetinib reported a higher response rate than
with chemotherapy alone [8].
Pazopanib is an orally bioavailable, multi-target tyrosine kin-
ase inhibitor of vascular endothelial growth factor receptors 1, 2,
and 3 (VEGFR1, 2, 3), platelet-derived growth receptors a and b
(PDGFR a and b), and stem cell factor receptor (c-KIT). As well
as its antiangiogenic effects, pazopanib inhibits MEK and ERK
activation at clinically relevant doses [9]. Trametinib is a revers-
ible, highly selective, allosteric inhibitor of MEK1/2 activation.
Both pazopanib and trametinib can safely be given with weekly
paclitaxel chemotherapy at the full monotherapy dose and
showed promising activity in BRAF-wt melanoma in early clinical
studies [10].
We therefore undertook the PACMEL phase II trial to better
assess the benefits and safety of adding trametinib or pazopanib
to paclitaxel chemotherapy in BRAF-wt unresectable or metastat-
ic melanoma.
Methods
Participants
This randomised, multicentre phase II trial was conducted in 26 centres
in the UK and Germany. Participants were 18 years or older with measur-
able unresectable BRAF-wt stage 3 or 4 melanoma, an Eastern
Cooperative Oncology Group (ECOG) score of 0 or 1, and acceptable
haematological, renal, and hepatic function. Patients were excluded if
they had received a prior MEK inhibitor or taxane, had grade2 periph-
eral neuropathy, had undergone recent systemic therapy or radiotherapy,
or had a recent history of another active malignancy. Patients with muco-
sal or ocular melanoma or with ocular disease that predisposed them to
central serous retinopathy or retinal vein occlusion were excluded.
The study protocol was approved by the independent ethics commit-
tee or independent review board at each study centre. All patients pro-
vided written consent to participate before screening procedures. The
study was conducted in accordance with the Declaration of Helsinki and
Good Clinical Practice guidelines.
Study design and treatment
PACMEL phase II was an open-label, multicentre, and randomised trial
that evaluated paclitaxel in combination with trametinib or pazopanib.
Eligible patients were randomised 1 : 1 : 1 to receive single-agent pacli-
taxel or paclitaxel combined with trametinib or pazopanib, stratifying for
NRASmutation status, lactate dehydrogenase level (LDH; elevated versus
within normal limits), and prior therapy for metastatic melanoma (yes
versus no), using minimisation with a random element of 0.8.
Randomisation was administered by a central trials unit to maintain
allocation concealment. Participants, investigators, and outcome asses-
sors were unblinded to treatment allocation.
Paclitaxel (80mg/m2 in the single-agent paclitaxel and paclitaxel–tra-
metinib arms, 65mg/m2 in the paclitaxel–pazopanib arm) was adminis-
tered intravenously on days 1, 8, and 15 of each cycle for up to a
maximum of six cycles. Trametinib (2mg, determined during PACMEL
phase I) or pazopanib (800mg) were administered orally once daily until
disease progression or unacceptable toxicity. Dose reductions of pacli-
taxel, trametinib, and pazopanib were permitted for toxicity.
End points
The primary end point was progression-free survival (PFS) using
Response Evaluation Criteria in Solid Tumours (RECIST) v1.1.
Secondary end points included overall survival (OS), objective response
rate (ORR), 6-month progression-free percentage, safety, and tolerabil-
ity. Adverse events (AEs) were graded according to the Common
Toxicity Criteria for Adverse Events (CTCAE) version 4.03.
Assessments
At screening, prospective participants gave a medical history and under-
went a full physical examination; ophthalmological evaluation; preg-
nancy test; 12-lead ECG; echocardiography; computed tomography (CT)
of the head, chest, abdomen, and pelvis; urinalysis; haematology; coagu-
lation and blood chemistry testing; and NRAS and BRAF mutation
assessment.
Participants underwent a targeted physical assessment, AE documen-
tation, urinalysis, and full blood chemistry and haematology testing be-
fore each paclitaxel dosing. Participants on trametinib or pazopanib
underwent echocardiography at baseline and weeks 4 and 12, then every
12weeks whilst on treatment. All participants underwent repeat CT
assessments at weeks 7, 15, and 23, then every 3months until disease pro-
gression. All participants underwent additional ophthalmological exam-
ination as clinically indicated.
Statistical analysis
We planned to recruit 120 patients, randomised 1 : 1 : 1 to allow inde-
pendent comparison of each combination arm with single-agent pacli-
taxel. PFS analysis was planned after 58 events in each comparison, giving
80% power to detect a hazard ratio of 0.57, with a one-sided a level of
0.10. Recruitment was significantly slower than anticipated, allowing a
revised minimum of 104 patients to deliver the required number of
events. All statistical analyses were pre-specified in the statistical analysis
plan that was signed off before the data analysis.
All efficacy analyses were carried out on an intention-to-treat basis,
analysing all randomised patients according to the treatment arm to
which they were randomised. Median follow-up time was calculated
using the reverse Kaplan–Meier method. Patients who withdrew consent
for further follow-up were censored at the time of withdrawal.
PFS was defined as the time from the date of randomisation to the date
of progression or death from any cause, whichever came first. PFS at
6months was defined as the Kaplan–Meier estimate percentage of partic-
ipants who were progression-free at 6months, with a 90% confidence
interval (CI). Participants without an event were censored at the time of
their last assessment. OS was defined as the time from the date of ran-
domisation to the date of death. Participants without an event were again
censored at the date of their last visit. ORR was defined as the best overall
response for each participant, portrayed as the proportion of participants
achieving a complete or partial response out of all randomised
participants.
The PFS and OS were compared between treatment arms using Cox
regression analysis, adjusting for the stratification variables.
The proportional hazard assumption was then checked using Schoenfeld
residuals. If the assumption was not met, then the Cox regression
results were not considered valid and were not to be reported. Instead,
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the analysis used an accelerated failure time (AFT) model as specified in
the Statistical Analysis Plan [11] (supplementary Figure S1, available
at Annals of Oncology online) AFT results are reported as a time ratio
(TR) with 90%CI.
The ORR was compared between treatment groups using the v2 test
and odds ratios. Safety analyses were carried out on patients who received
at least one treatment dose. AEs grade 3 and serious AEs (SAEs) be-
tween treatment groups were compared using the v2 test.
A sensitivity analysis was carried out on the per-protocol population
to examine the robustness of the intention-to-treat analysis conclusions.
A sub-group analysis was planned comparing outcomes in theNRASmu-
tant and wild-type subgroups.
STATA v14.1 (StataCorp, College Station, TX) was used in all analyses.
All reported P-values are two-sided for the primary and secondary analyses.
Results
Participants and treatment
Between April 2012 and March 2016, 382 patients were consid-
ered for the trial at 26 sites in the UK and Germany. We rando-
mised 111 patients to treatment (paclitaxel, n¼ 38, paclitaxel–
trametinib, n¼ 36, and paclitaxel–pazopanib, n¼ 37). Although
smaller than the calculated sample size, this sample provided the
required number of events to achieve the power calculated and
all 111 were included in the efficacy and safety analyses
(Figure 1). The most common reasons for non-participation
were patients declining to participate (85 patients), melanoma
with BRAF mutation (33 patients), evidence of brain metastases
(33 patients), and uncontrolled co-morbidities (15 patients).
Participant demographics and baseline clinical characteristics
(Table 1) were well balanced across the three arms. Most (64%) of
the patients were treatment-naı¨ve.
Paclitaxel was given for a median 3, 6, and 4 cycles as a single
agent, with trametinib, and with pazopanib, respectively. Six cycles
of paclitaxel treatment were completed by 19% of participants as a
single agent, 42% in the paclitaxel–trametinib arm, and 20% in the
paclitaxel–pazopanib arm. The main reasons for discontinuing
paclitaxel treatment were progressive disease (62% single-agent
paclitaxel, 49% paclitaxel–trametinib, and 43% paclitaxel–pazopa-
nib) and toxicity (8% single-agent paclitaxel, 6% paclitaxel–trame-
tinib, and 32% paclitaxel–pazopanib). The inhibitor agent was
taken for more than 4months by 17 (47%) participants on trame-
tinib and 11 (30%) participants on pazopanib.
Assessed for eligibility and consent
(n = 382)
Excluded (n = 271)
  Not meeting inclusion criteria (n = 185)
       BRAF-wt melanoma (n = 33)
       Evidence of brain metastases (n = 33)
       Uncontrolled co-morbidities (n = 15)
       Pathology/biochemistry results (n = 14)
       Twelve other specified inclusion criteria
                                                                (n = 75)
       Specific inclusion criteria not given (n = 15)
  Declined to participate (n = 85)
  Other reasons (n = 1)
Randomised
(n = 111)
Allocated to paclitaxel (n = 38)
Received allocated intervention
(n = 38)
Allocated to paclitaxel and
trametinib (n = 36)
Received allocated intervention (n = 36)
Allocated to paclitaxel and
pazopanib (n = 37)
Received allocated intervention (n = 37)
Analysed Analysed
  ITT population (n = 36)
 Safety population (n = 36)
Analysed
  ITT population (n = 37)
 Safety population (n = 37)
ITT population (n = 38)
Safety population (n = 38)
Figure 1. CONSORT diagram.
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Efficacy
After 95 events, the median PFS was 3.4months (90% CI 2.0–3.8)
with paclitaxel alone, 5.2months (90% CI 3.7–7.0) with paclitaxel
and trametinib, and 5.3months (90% CI 3.4–6.4) with paclitaxel
and pazopanib (Table 2). There were more than 58 events in each
of the pairwise comparisons, as required for the calculated power.
A Cox regression was run for the PFS analysis and the propor-
tional hazard assumption checked. As the assumption failed, Cox
Table 1. Patient characteristics at baseline
Characteristics Paclitaxel (n5 38) Paclitaxel1trametinib (n5 36) Paclitaxel1pazopanib (n537)
Age, years, median (range) 64 (35–80) 60 (27–80) 66 (41–80)
Gender male, n (%) 27 (71) 23 (64) 25 (68)
Ethnicity, n (%)
White 35 (92) 33 (92) 34 (92)
Other ethnic groups 2 (5) 2 (6) 2 (5)
Not given 1 (3) 1 (3) 1 (3)
ECOG performance score, n (%)
0 21 (55) 23 (64) 25 (68)
1 17 (45) 13 (36) 12 (32)
Disease stage at entry, n (%)
IV 38 (100) 34 (94) 34 (92)
Unresectable stage III 0 (0) 2 (6) 3 (8)
Stratification variables, n (%)
Prior therapy 13 (34) 12 (33) 14 (38)
LDH within normal range 19 (50) 18 (50) 18 (49)
NRAS mutant 14 (37) 14 (39) 18 (49)
n, number of patients in a group; LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group.
Table 2. Summary of clinical outcomes by treatment arm
End point Paclitaxel (n5 38) Paclitaxel1trametinib (n5 36) Paclitaxel1pazopanib (n537)
Progression-free survival (months)
Median duration (90% CI) 3.4 (2.0–3.8) 5.2 (3.7–7.0) 5.3 (3.4–6.4)
TRa (90% CI) 1.0 1.47 (1.08–2.01) P ¼ 0.04 1.36 (0.96–1.93) P ¼ 0.14
Progression-free survival rate at 6 months
Percentage (90% CI) 27 (16–40) 39 (26–52) P ¼ 0.27 41 (28–55) P ¼ 0.18
Overall survival (months)
Median duration (90% CI) 10.8 (8.8–not reached) 9.4 (8.3–13.5) 11.6 (8.0–16.2)
TR (90% CI) 0.71 (0.44–1.11) P ¼ 0.18 0.87 (0.71–1.09) P ¼ 0.34
Response to treatment
Complete response 2 0 0
Partial response 3 15 8
Stable disease 13 11 16
Progressive disease 13 6 9
Not evaluated 7 4 4
Duration of responseb (months)
Median duration (90% CI) 3.8 (0.6–not reached) 3.6 (1.9–6.6) 4.6 (3.1–5.5)
ORRc, n (%) 5 (13) 15 (42) P ¼ 0.01 8 (22) P ¼ 0.34
Odds ratio (90% CI) 1.0 4.7 (1.7–13.2) P ¼ 0.01 1.82 (0.6–5.2) P ¼ 0.34
All P-values reported are two-sided; P-value <0.1 was considered to be significant.
aAs the Cox model did not fit, the accelerated failure time model was used, as required in the analysis plan, giving time ratios. A TR above 1 implies that
the covariate prolongs the time to event.
bMedian duration of response from Kaplan–Meir graph of time from best overall response (whether complete or partial response) to relapse or death.
cORR, the best overall response for each patient portrayed as the proportion of achieving complete response or partial response out of patients
randomised.
CI, confidence interval; TR, time ratio; OR, odds ratio; n, number of patients in a group; ORR, objective response rate.
Original article Annals of Oncology
4 | Urbonas et al.
regression was not considered a valid method here and the results
are not reported. Following the pre-specified statistical analysis
plan, an AFT model was used instead to analyse PFS. PFS was sig-
nificantly longer in the paclitaxel–trametinib arm than in single-
agent paclitaxel (TR 1.47; 90% CI 1.08–2.01; two-sided P¼ 0.04).
There was no difference in PFS between the paclitaxel–pazopanib
and single-agent paclitaxel arms (TR 1.36; 90% CI 0.96–1.93;
two-sided P¼ 0.14) (Figure 2A; Table 2).
ORR was significantly higher with paclitaxel and trametinib
than with single-agent paclitaxel (42% versus 13%, two-sided
P¼ 0.01), but paclitaxel and pazopanib showed no improvement
over single-agent paclitaxel (22% versus 13%, two-sided
P¼ 0.34) (Table 2).
The PFS rates at 6months were 27%, 39%, and 41% in the
single-agent paclitaxel, paclitaxel–trametinib, and paclitaxel–
pazopanib groups, respectively. There was no significant differ-
ence in 6-month PFS rate between the paclitaxel–trametinib and
single-agent paclitaxel arms (two-sided P¼ 0.27) or the pacli-
taxel–pazopanib and single-agent paclitaxel arms (two-sided
P¼ 0.18).
After a median follow-up of 25.9months (90% CI 20.1–
32.9) and 66 deaths, the median OS was 10.8 months (90% CI
8.8–not reached) in the paclitaxel group, 9.4months (90% CI
8.3–13.5) in the paclitaxel–trametinib group and 11.6 months
(90% CI 8.0–16.2) in the paclitaxel–pazopanib group
(Table 2). Due to the AFT model being required for PFS, it was
also used for the OS analysis. The OS was not significantly dif-
ferent between the paclitaxel–trametinib and single-agent
paclitaxel arms (TR 0.71; 90% CI 0.44–1.11; two-sided
P¼ 0.18) or paclitaxel–pazopanib and single-agent paclitaxel
TR (PT vs P) = 1.47 (90%CI, 1.08 to 2.01)
TR (PP vs P) = 1.36 (90%CI, 0.96 to 1.92)
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Figure 2. Kaplan–Meier curve for (A) progression-free survival and (B) overall survival with the time ratio (TR) calculated using a log-logistic
accelerated failure time model.
Annals of Oncology Original article
doi:10.1093/annonc/mdy500 | 5
arms (TR 0.87; 90% CI 0.70–1.09; two-sided P¼ 0.34)
(Figure 2B; Table 2).
A sensitivity analysis repeating all tests using the per-protocol
population gave broadly similar results to the intention-to-treat
population, so is not reported in detail. As samples sizes were
too small for the planned subgroup analysis comparing out-
comes in NRAS mutant and wild-type, the results are not
reported here.
Safety
All of the 111 randomised participants who received treatment were
included in the safety analysis. Almost all (109, 98%) experienced an
AE. Rash was more prevalent in participants taking trametinib.
Transaminitis and altered taste were more prevalent in those on
pazopanib. Participants who were assigned targeted therapy experi-
enced anorexia more frequently. Grade 3 or higher AEs were
recorded in 9 (24%) of the 38 patients in the single-agent paclitaxel
group, 27 (75%)of the 36 patients in the paclitaxel–trametinib group,
and 29 (78%) of the 37 patients in the paclitaxel–pazopanib group
(Table 3). Nineteen (54%) participants receiving paclitaxel–pazopa-
nib stopped taking pazopanib due to toxicities, whereas 6 (18%) par-
ticipants receiving paclitaxel–trametinib stopped taking trametinib.
Seventy-two serious AEs (SAEs) were reported in 47 patients.
The incidence of SAEs was higher when paclitaxel was combined
with trametinib (47%) or pazopanib (67%) than when given
alone (13%). Deaths during study treatment or within 35 days of
the last study medication were reported for two participants on
paclitaxel and pazopanib and one participant taking paclitaxel
and trametinib. One participant in the paclitaxel–pazopanib arm
died of pneumonia that was likely to have been related to
paclitaxel-induced myelosuppression. Another participant in the
same group died of bowel perforation related to disease progres-
sion, however, we were unable to exclude a contribution from
pazopanib. One patient in the paclitaxel–trametinib arm died
due to disease progression.
Discussion
Although patients with BRAF-mutant melanoma have access to
effective targeted treatments, these do not yet exist for BRAF-wt
melanoma. Effective treatment options are urgently needed for
patients with BRAF-wt melanoma, particularly those with rapidly
progressive disease.
As melanoma is almost always associated with an activated
MAPK pathway, even in tumours not driven by BRAF mutation,
MEK inhibition is a promising therapeutic strategy. However, the
activity of MEK inhibitors in BRAF-mutant melanoma has not
been replicated in other genotypes [12]. Binimetinib showed an
ORR of 20% and a median PFS of 4months in BRAF-wt NRAS-
mutant melanoma patients in a phase II trial [13]. However, in
the randomised, phase III NEMO trial, the median PFS was only
2.8months, ORR was 15%, and OS was not statistically
Table 3. Incidence of treatment-related adverse events
AEs Paclitaxel (n5 38) Paclitaxel1trametinib (n5 36) Paclitaxel1pazopanib (n537)
n (%)
Any grade AEs 36 (95) 36 (100) 37 (100)
Grade 3 AEs 9 (24) 27 (75) 29 (78)
Fatal AEs 0 (0) 1 (4) 2 (5)
AE per patient for AEs affecting 15 or more patientsa,b n (n of grade 3 or more)
Rash 6 (0) 35 (14) 9 (0)
ALT increased 1 (0) 2 (0) 12 (9)
Fatigue 19 (1) 24 (4) 18 (3)
Dyspnoea 8 (1) 10 (1) 8 (2)
Abdominal pain 7 (0) 11 (1) 14 (2)
Diarrhoea 17 (0) 24 (2) 20 (1)
Nausea 11 (0) 12 (0) 16 (1)
Anaemia 3 (0) 6 (2) 8 (0)
Alopecia 17 (1) 13 (0) 13 (0)
Anorexia 6 (0) 13 (0) 11 (0)
Constipation 11 (0) 13 (0) 2 (0)
Dysgeusia 3 (0) 4 (0) 12 (0)
Dyspepsia 7 (0) 4 (0) 4 (0)
Epistaxis 4 (0) 9 (0) 6 (0)
Headache 2 (0) 6 (1) 7 (0)
Vomiting 6 (0) 5 (0) 9 (0)
Cough 8 (0) 5 (0) 5 (0)
aThe AE terms are ranked according to the highest frequency of grade 3.
bIn any one row, a patient appears only once whether they had one episode of the AE or many.
AE, adverse events measured by Common Terminology Criteria for Adverse Events V4.03; ALT, alanine aminotransferase; n, number of patients in a group.
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significantly different from that achieved with dacarbazine
chemotherapy [14].
Our study showed superior PFS for paclitaxel and trametinib
compared with paclitaxel chemotherapy alone. These results
were obtained even though half of the patients had elevated LDH
and nearly 40% a mutation in tumour NRAS, both of which are
associated with poor prognosis. The outcomes with paclitaxel
alone were consistent with published data from larger studies,
providing evidence that the improvements seen in PFS and ORR
when trametinib was added cannot be explained by poor per-
formance in the control arm [15, 16].
However, the significant difference in PFS did not translate
into an improvement in OS. This is consistent with the modest
durability of responses in all three study arms, at around
4months. Post-progression treatment with immunotherapy may
also have influenced this outcome. Most of the participants had
not received prior systemic therapy, as there was limited availabil-
ity of checkpoint inhibitors early in the life of this trial. The
NEMO trial and a study of docetaxel with or without selumetinib
inNRAS-mutant non-small-cell lung cancer also found a PFS ad-
vantage that did not yield an OS benefit [17]. Thus, the biological
effects of MEK inhibition may be rapidly overcome by BRAF-wt
tumours, perhaps due to the loss of negative feedback mecha-
nisms under MEK inhibition.
The median PFS observed at 5.2months when combining
paclitaxel and trametinib was superior to that observed with bini-
metinib alone in phase II and III (NEMO) melanoma trials [13,
14]. The patient populations in the current study andNEMO trial
were different, as we included patients with neither NRAS- nor
BRAF-mutant melanoma. However, PACMEL included a higher
proportion of participants with elevated LDH. The MEK
inhibitor-chemotherapy combination regimen’s tolerability was
similar to that of binimetinib alone, with 6 of the 33 (18%) partic-
ipants discontinuing treatment because of toxicity in our pacli-
taxel–trametinib arm, compared with 20% of binimetinib-
treated patients in the NEMO study.
The improved outcomes in the paclitaxel–trametinib arm
came at the cost of more AEs than when using paclitaxel alone,
with 75% of patients experienced a grade 3 or higher toxicity.
The paclitaxel pazopanib combination also caused grade 3 or
4 AEs in three quarters of patients and over half of the partici-
pants had to discontinue treatment, mainly due to
hepatotoxicity.
In conclusion, the PACMEL phase II trial found that adding
the MEK inhibitor trametinib to paclitaxel chemotherapy signifi-
cantly improved PFS and ORR in patients with BRAF-wt melan-
oma, but did not impact OS.
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